Zapping the brain to beat opioid relapse: new study tests Non-Invasive technique
NCT ID NCT03773523
First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 2 times
Summary
This study tests a new approach to help people recovering from opioid use disorder avoid relapse. About 90% of people in treatment relapse within a year. Researchers will use a gentle, non-invasive brain stimulation method called tDCS combined with cognitive training to see if it can change brain connections linked to craving. The study involves 30 adults who are already abstinent and living in a supervised program.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2019
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 20 abstinent individuals (18-60 years old; 1-2 weeks of abstinence) who meet DSM-V criteria for opioid use disorder (OUD) will be recruited from the Lodging Plus Program, part of University of Minnesota Medical Center * This 28-day program provides a supervised environment to treat individuals with OUD in which patients receive random drug screenings. Lodging Plus has 50 beds and admits an average of 20 patients per week and about 50% of patients admitted have a diagnosis of opioid use disorder. * Ability to provide written consent and comply with study procedures, meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnostic criteria for OUD. Subjects may have current comorbid drug use, but their primary substance use disorder diagnosis needs to be based on opioid use. Subjects must have the intention to remain in the Lodging Plus program (4 weeks) until the end of the intervention portion of the study. Vulnerable populations will not be included. Exclusion Criteria: * Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness\>30 min, HIV) * A head injury resulting in a skull fracture or a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI) * Any contraindications for tDCS or MRI scanning (tDCS contraindication: history of seizures; MRI contraindications; metal implants, pacemakers or any other implanted electrical device, injury with metal, braces, dental implants, non-removable body piercings, pregnancy, breathing or moving disorder) * DSM-V criteria for psychiatric disorder, may have a lifetime diagnosis of depression * Presence of a condition that would render study measures difficult or impossible to administer or interpret * Age outside the range of 18 to 60 * Primary current substance use disorder diagnosis on a substance other than opioid except for caffeine or nicotine * Clinical evidence for Wernicke-Korsakoff syndrome * Nicotine use will be recorded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Opioid abuse are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55414, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise boost brain and body health during opioid treatment?
- Can a new drug calm the storm of opioid withdrawal?
- Can coaching turn rural clinics into One-Stop shops for addiction and infectious disease care?
- Can a Phone-Based platform keep people in opioid treatment?
- A safety net after jail: can checkups keep opioid treatment on track?
- Can AI and peer support close the opioid treatment gap?